A detailed history of Israel Englander (Millennium Management LLC) transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 46,335 shares of SLS stock, worth $56,528. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,335
Previous 150,448 69.2%
Holding current value
$56,528
Previous $179,000 68.16%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.08 - $1.39 $112,442 - $144,717
-104,113 Reduced 69.2%
46,335 $57,000
Q2 2024

Aug 14, 2024

BUY
$1.06 - $1.63 $159,474 - $245,230
150,448 New
150,448 $179,000
Q4 2023

Feb 14, 2024

BUY
$0.88 - $1.57 $9,890 - $17,645
11,239 New
11,239 $11,000
Q4 2022

Feb 14, 2023

BUY
$1.8 - $5.41 $65,512 - $196,902
36,396 Added 146.86%
61,179 $144,000
Q3 2022

Nov 14, 2022

BUY
$2.02 - $3.38 $50,061 - $83,766
24,783 New
24,783 $50,000

Others Institutions Holding SLS

About SELLAS Life Sciences Group, Inc.


  • Ticker SLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,551,900
  • Market Cap $25.1M
  • Description
  • SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...
More about SLS
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.